Rapid Screening Analysis for Barbiturates in Human Urine by GC-TOFMS with the Pegasus BT

Significance of the Topic

Rapid and reliable screening for barbiturates in human urine is critical for forensic toxicology, clinical diagnostics, and workplace drug testing. Barbiturates remain important analytes due to their therapeutic and illicit use. High-throughput methods that maintain sensitivity and specificity help laboratories manage growing sample volumes while ensuring regulatory compliance.

Objectives and Study Overview

This study aimed to develop and validate a fast, simple workflow for detecting five barbiturates in human urine using gas chromatography–time-of-flight mass spectrometry (GC-TOFMS) on the Pegasus® BT platform. The specific goals were:

• Minimize sample preparation time without derivatization.
• Achieve chromatographic separation and full-spectral identification in under nine minutes.
• Demonstrate limits of detection below federal cutoff levels.
• Validate calibration linearity over a wide concentration range.

Methodology and Instrumentation

Human urine was treated with urease, basified, and extracted with dichloromethane. The organic phase was dried, evaporated under nitrogen, and reconstituted in chloroform. Standards of butalbarbital, amobarbital, pentobarbital, secobarbital, and phenobarbital were spiked at concentrations from 5 to 500 ng/mL. Data acquisition combined automated NonTarget Deconvolution™ with Target Analyte Finding for qualitative and quantitative analysis.

Used Instrumentation:

• Agilent 7890 GC with MPS2 Autosampler
• Rxi-5ms capillary column (20 m × 0.18 mm, 0.18 μm film)
• LECO Pegasus BT TOFMS (mass range 35–650 m/z, 20 spectra/s)
• Helium carrier gas at 1.4 mL/min, GC oven ramp 50 °C to 320 °C at 50 °C/min

Main Results and Discussion

Complete separation of five barbiturates was achieved in under five minutes. Calibration curves exhibited excellent linearity (r ≥ 0.998) across 5–500 ng/mL. Limits of detection ranged from 0.5 to 5 ng/mL, substantially below U.S. federal cutoff levels (200 ng/mL). Automated deconvolution produced high-quality spectral data, with library similarity scores above 866/1000 for all analytes. The workflow proved robust against matrix interferences commonly encountered in urine extracts.

Benefits and Practical Applications

The method offers:

• Fast turnaround (<9 min per sample) for high-throughput laboratories.
• Simplified sample preparation without chemical derivatization.
• Reliable identification and quantitation well below regulatory thresholds.
• Automated data processing suited for routine forensic and clinical screening.

Future Trends and Opportunities

Advancements in GC-TOFMS instrumentation and data analysis software will further reduce analysis time and improve sensitivity. Integration with high-resolution mass spectrometry and machine-learning algorithms promises enhanced deconvolution in complex matrices. Expanding non-targeted screening libraries will enable simultaneous detection of emerging psychoactive substances alongside legacy drugs.

Conclusion

The Pegasus BT GC-TOFMS platform delivers a rapid, sensitive, and streamlined approach for barbiturate screening in urine. With robust performance below federal cutoff levels and strong calibration linearity, this method meets the demands of forensic and clinical laboratories for fast, accurate drug analysis.

Reference

1. U.S. Nuclear Regulatory Commission. “26.163 Cutoff Levels for Drugs and Drug Metabolites,” Dec. 2015.
2. Substance Abuse and Mental Health Services Administration. “Clinical Drug Testing in Primary Care–TAP 32,” Dec. 2012.